Prostate cancer is the most common cancer affecting men. Androgen deprivation therapy (ADT) is accepted as the primary treatment modality of advanced or metastatic prostate cancer. Erectile dysfunction and loss of libido are well-known side effects of ADT. In the previous studies, androgens have been demonstrated to play an important role in erectile physiology. However, the molecular mechanisms involving this issue have not been completely understood yet. The objective of this review is the assessment of ADT's effects on sexual functions in light of the current literature.